History of Avanir

1988

Founded with focus

Avanir started out as Lidak Pharmaceuticals, Inc. in 1988, developing research-based treatments to meet patient needs. Our first pharmaceutical product was Abreva®, an over-the-counter cold sore treatment that was out-licensed to another company.

microscope-icon.png

1990s

Becoming Avanir

Our quest to bring research-based treatments to patients led us to develop treatments for cardiovascular, autoimmune and infectious diseases. We also changed our name to Avanir Pharmaceuticals, Inc.

1999

CNS at the Forefront

During this pivotal year, we began development of products containing dextromethorphan – a key ingredient in our CNS-focused approved product and many drugs under development.

humanbrain-icon.png

2007

Moving Up

Avanir became a publicly traded company, listed on the NASDAQ stock exchange.

2010

NUEDEXTA® Approved

In October, we received an FDA approval for NUEDEXTA® (dextromethorphan hydrobromide and quinidine sulfate) with a 20/10 mg dose strength.

2011

NUEDEXTA® is launched in the United States

nuedexta-boxset.jpg

2012

R&D Progress

We entered into a license agreement with Concert Pharmaceuticals, Inc. to develop and commercialize deuterium-modified dextromethorphan for disorders of the central nervous system.

concert-history.png
avanir-logo-history.png

NUEDEXTA®
EU Approval*

In June, the European Commission approved NUEDEXTA®  (dextromethorphan hydrobromide and quinidine sulfate) with a 20/10 and 30/10 mg dose strength.

*product is currently not marketed in Europe

On July 2, we announced a development and commercialization agreement with OptiNose AS for a new investigational product for the acute treatment of migraine.

2015

Joining Otsuka

In 2015, Avanir became a subsidiary of Otsuka America, Inc., a holding company owned by Otsuka Pharmaceutical Co., Ltd. This move provided the support of a leading global pharmaceutical company while allowing our business to remain nimble and flexible.

otsuka-history.png

2016

ONZETRA® Xsail® approved

(sumatriptan nasal powder) 11 mg per nosepiece

We received FDA approval of ONZETRA® Xsail® in January and launched it in the United States market in May.

onzetra-device-red.jpg